CLINICAL STUDIES ON BRL25000 (CLAVULANIC ACID-AMOXICILLIN) IN THE FIELD OF INTERNAL MEDICINE

BRL25000, one tablet of the drug containing 250 mg of AMPC and 125 mg of CVA, was administered to 13 patients with urinary or pulmonary infections. Effective results were obtained in 9 out of 10 cases with urinary infections, and one out of 3 cases with pulmonary infections. No side effects except 1...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 30; no. Supplement2; pp. 269 - 272
Main Authors MIURA, KENSUKE, SAWADA, HIROYOSHI, IZUMI, YOICHIRO, UCHINO, HARUTO, KINOSHITA, RYOTA, USUI, TADAO, KONISHI, HIROSHI, ISHIKURA, HIROTO, KONISHI, AKEMI
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 25.11.1982
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.30.Supplement2_269

Cover

More Information
Summary:BRL25000, one tablet of the drug containing 250 mg of AMPC and 125 mg of CVA, was administered to 13 patients with urinary or pulmonary infections. Effective results were obtained in 9 out of 10 cases with urinary infections, and one out of 3 cases with pulmonary infections. No side effects except 1 case with abdominal pain and diarrhea, were observed. This drug shows very strong antibacterial activity against several strains which are resistant to AMPC. These include E. coli, K. pneumoniae, P. mirabilis and E. cloacae. It is considered that BRL25000 may constitute an advance to the antibiotic treatment of β-lactamase proplucing bacterial infections.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.30.Supplement2_269